Evidence map›Paper›PMID 41170156›Full record

ReviewPrecision chemistry2025

Advances in Epigenomic Sequencing and Their Applications in Cancer Diagnostics.

Liyun Lin, Yang Liu

Abstract readReview
In one paragraph

Review in Precision chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Advances in spatial omics for the analysis of prostate cancer.Analytical and bioanalytical chemistry · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Liyun LinDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut 06510, United States.
Yang LiuDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut 06510, United States.ORCID https://orcid.org/0000-0003-1830-948X

Funding

Spatially resolved multiomics profiling of microbes and their host tissueR35GM150838 · NIGMS · YALE UNIVERSITY · PI Yang Liu · 2023 to 2026
$1.7M
Unraveling molecular Complexity of Mitral Valve Disease using single cell and Spatial Multi-Omics analysis"R01HL173271 · NHLBI · YALE UNIVERSITY · PI Yang Liu · 2024 to 2026
$1.4M
NHLBI NIH HHS R01 HL173271NIGMS NIH HHS R35 GM150838
6 · The paper itself

Abstract

Cancer, a globally prevalent and life-threatening disease, remains a major area of focus in biomedical research. However, its substantial heterogeneity and complex pathogenesis continue to pose significant challenges for accurate diagnosis and effective treatment. The rapid advancement of epigenomic sequencing technologies has opened avenues by uncovering the epigenetic hallmarks and underlying pathology of cancer. As a result, these technologies have become invaluable tools in advancing cancer diagnostics and connecting research with clinical applications. This review briefly overviews epigenomic modifications and their significance in cancer diagnostics, highlighting potential epigenomic biomarkers with clinical applicability. We also examine emerging techniques in bulk and single-cell sequencing approaches, alongside spatial tools, highlighting their integration with multiomics technologies for cancer diagnostics. Particular attention is given to the analysis of key epigenetic characteristics, such as DNA methylation, histone modifications, and chromatin accessibility. Additionally, we summarize the diagnostic applications of these technologies and evaluate their current adoption in clinical settings. Challenges, limitations, and future directions for advancing epigenomic sequencing toward routine clinical diagnostics are also discussed. This review aims to provide scientists and clinicians with a comprehensive resource, encouraging further exploration and adoption of epigenomic sequencing technologies to drive progress in precision medicine.

Indexed as

cancer diagnosticschromatin accessibilityDNA methylationepigenomicshistone modificationssequencingsingle-cellspatial

Identifiers

PMID41170156
PMCPMC12569958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.